Difference between revisions of "Arrhythmogenic Right Ventricular Cardiomyopathy"

From ECGpedia
Jump to navigation Jump to search
m (New page: ===Wat is ARVD?=== [[Image:arvdhart.png|thumb| Doorsnede van het hart van een patiënt met ARVD. (A) Transmurale vervetting van de vrije wand van de rechter kamer. (B) De myocardiale atrof...)
 
m
 
(60 intermediate revisions by 9 users not shown)
Line 1: Line 1:
===Wat is ARVD?===
+
{{authors|
[[Image:arvdhart.png|thumb| Doorsnede van het hart van een patiënt met ARVD. (A) Transmurale vervetting van de vrije wand van de rechter kamer. (B) De myocardiale atrofie is beperkt tot de rechter kamer, de linker kamer en het interventriculaire septum zijn gespaard gebleven. <cite>Corrado</cite> Reproduced with permission from BMJ Publishing Group Ltd. ]]
+
|mainauthor= [[user:Drj|J.S.S.G. de Jong, MD]]
Aritmogene Rechter Ventrikel Dysplasie, ARVD of ARVC (cardiomyopathie) is een ziekte dat gekenmerkt wordt door vervetting en fibrosering van het hart. Met name de rechter ventrikel (apex), de rechter ventrikel uitstroombaan en de rechter ventrikel vrije wand , net onder de triscupidalis kleppen zijn het meest aangedaan. Meestal is de rechter ventrikel aangedaan, maar de linker kamer kan ook betrokken zijn.  
+
|advisor=
 +
|coauthor=
 +
|moderator= [[user:Drj|J.S.S.G. de Jong, MD]]
 +
|editor= P.G. Postema, MD
 +
}}
 +
[[Image:epsilon_wave.png|thumb|ECG with an epsilon wave in V1]]
 +
[[Image:arvdhart.png|thumb| A section throughout the heart of an ARVC patient. (A) Transmural fatty replacement of the right ventricular free wall. (B) Myocardial atrophy is confined to the right ventricle and substantially spares the interventricular septum as well as the left ventricular free wall. <cite>Corrado</cite> Reproduced with permission from BMJ Publishing Group Ltd. ]]
 +
'''Arrhythmogenic Right Ventricular Cardiomyopathy''', (ARVC, or ARVD: Arrhythmogenic Right Ventricular Disease) is characterized by fatty replacement and fibrosis of the heart. Most commonly the right ventricle apex and outflow tract are involved. However the left ventricle can be affected too.<cite>Corr</cite>
  
Door de vervetting en fibrosering ontstaan er makkelijk kamerritmestoornissen, die zich kunnen uiten als palpitaties, duizeligheid, syncope (flauwvallen) of plotselinge dood. Op latere leeftijd kan ook rechterkamerfalen optreden door een verminderde pompkracht.
+
As a result of the fatty replacement and fibrosis, ventricular arrhythmias are common in this disease and can lead to palpitations, syncope and sudden death. At more advanced ages right ventricular pump failure can occur.
  
De diagnose wordt gesteld op basis van major en minor criteria van de European Society of Cardiology.<cite>McKenna1994</cite>
+
The diagnosis is based on major and minor criteria, as published by the European Society of Cardiology.<cite>McKenna1994</cite>
  
ARVD is een progressieve ziekte. De incidentie wordt geschat op 1:3.000-1:10.000. De ziekte presenteert zich vooral in de tienerleeftijd. Hoewel de ziekte vaker bij atleten wordt gezien, wordt het echter niet door sport veroorzaakt. ARVD kan familiair voorkomen; er zijn inmiddels 9 chromosomale afwijkingen gevonden in verschillende families. De ziekte lijkt autosomaal dominant over te erven.
+
ARVC is a progressive disease. The '''incidence''' is estimated to be 1:3.000-1:10.000. Manifestations are usually seen in teenagers. Although the diagnosis is more often made in athletes, sports are not thought to have a causative relationship with the disease. ARVD can occur in families; more than 9 different mutations have been described, most often with autosomal dominant inheritance.  
Hiernaast is er ook tenminste één duidelijk onderkende variant van ARVD (De ziekte van Naxos, naar het Griekse eiland waar een familie gevonden is met deze variant) die met een autosomaal recessief patroon overerft.
 
  
{{clr}}
+
One unique form of ARVD, called Naxos disease (after the Greek island where it was first diagnosed), has an autosomal recessive pattern of inheritance.
  
===Diagnose===
+
'''Diagnosis''' ARVC is a difficult diagnosis to make. Therefore, the European Society of Cardiology has created a list of diagnostic criteria for the diagnosis of ARVC<cite>#McKenna1994</cite> (see table). An [http://www.arvc.ca/pdg/public.php?rep=arvc_cri online calculator] can help in assessing the risk in an individual patient. In 2009 these criteria were updated<cite>cox</cite><cite>Crit2010</cite>, see the table below.
[[Image:epsilon_wave.png|thumb|Een epsilon golf in V1]]
 
De diagnose ARVD is niet makkelijk te stellen, behalve bij obductie. Op het ECG zijn soms een aantal karakteristieke afwijkingen te zien, namelijk:
 
* Epsilon golven
 
* Verlengde QRS duur (>110ms) in de precordiale afleidingen (V1–V3)
 
* Late potentialen op een [[signal averaged ECG]]
 
  
De European Society of Cardiology heeft een lijst van diagnostische criteria opgesteld waar iemand aan moet voldoen om de diagnose ARVD te stellen.
+
'''Treatment''' focuses on avoiding complications.<cite>ACC2006</cite>
{{clr}}
+
*Medication:
{| class="wikitable" align="right" width="400px"
+
**Anti-arrhythmics: Sotalol better than Amiodarone.
!Diagnostische criteria voor Aritmogene Rechter Ventrikeldysplasie <cite>McKenna1994</cite>
+
**ACE-inhibitors to prevent cardiac remodelling
 +
*[[ICD]] implantation is recommended for the prevention of sudden cardiac death in patients with ARVC with documented sustained VT or VF who are receiving chronic optimal medical therapy.
 +
*[[ICD]] implantation can be considered for the prevention of sudden cardiac death in patients with ARVC with extensive disease, including those with left ventricular involvement, 1 or more affected family member with SCD (Sudden Cardiac Death), or undiagnosed syncope when [[Ventricular Tachycardia|ventricular tachycardia]] or [[Ventricular Fibrillation|ventricular Fibrillation]] has not been excluded as the cause of syncope, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y.
 +
*Radiofrequency [[ablation]] can be useful as adjunctive therapy in management of patients with ARVC with recurrent [[Ventricular Tachycardia|ventricular tachycardia]], despite optimal antiarrhythmic drug therapy.
 +
== ECG in ARVD==
 +
On [http://www.arvd.org ARVD.org] the latest ECG criteria for ARVD are updated. To enhance detection of ECG abnormalities specific settings to record an ARVD ECG can be used: [http://arvd.org/ECG.pdf ECG settings to enhance recording of Epsilon waves].
 +
 
 +
In patients suspected to have ARVD both a normal 12 lead ECG and a Signal Averaged ECG ([[SAECG]]) are useful.
 +
 
 +
<gallery>
 +
Image:arvd_ecg1.png| a patient with ARVD
 +
Image:arvd_ecg2.png
 +
Image:arvd_ecg3.png
 +
</gallery>
 +
 
 +
== Revised Task Force Criteria ARVD / ARVC==
 +
{| class="wikitable" style="width:700px"
 +
|+ The Revised Task Force Criteria for ARVD / ARVC
 +
! colspan="2"  style="width:600px" | Revised Task Force Criteria
 +
|-
 +
| colspan="2" | '''I. Global or regional dysfunction and structural alterations<sup>&lowast;</sup>'''
 +
|-
 +
| style="width:300px" | '''Major'''
 +
| style="width:300px" | '''Minor'''
 +
|-
 +
| valign="top" style="padding-left:24px" |
 +
<strong>By 2D echo:</strong>
 +
* Regional RV akinesia, dyskinesia, or aneurysm
 +
* and 1 of the following (end diastole):
 +
** PLAX RVOT &ge;32 mm (corrected for body size [PLAX/BSA] &ge;19 mm/m<sup>2</sup>)
 +
** PSAX RVOT &ge;36 mm (corrected for body size [PSAX/BSA] &ge;21 mm/m<sup>2</sup>)
 +
** <em>or</em> fractional area change &le;33%
 +
<strong>By MRI:</strong>
 +
* Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
 +
* <em>and</em> 1 of the following:
 +
** Ratio of RV end-diastolic volume to BSA &ge;110 mL/m<sup>2</sup> (male) or &ge;100 mL/m<sup>2</sup> (female)
 +
** <em>or</em> RV ejection fraction &le;40%
 +
<strong>By RV angiography:</strong>
 +
* Regional RV akinesia, dyskinesia, or aneurysm
 +
| valign="top" |
 +
<strong>By 2D echo:</strong>
 +
* Regional RV akinesia or dyskinesia
 +
* <em>and</em> 1 of the following (end diastole):
 +
** PLAX RVOT &ge;29 to &lt;32 mm (corrected for body size [PLAX/BSA] &ge;16 to &lt;19 mm/m<sup>2</sup>)
 +
** PSAX RVOT &ge;32 to &lt;36 mm (corrected for body size [PSAX/BSA] &ge;18 to &lt;21 mm/m<sup>2</sup>)
 +
** <em>or</em> fractional area change &gt;33% to &le;40%
 +
<strong>By MRI:</strong>
 +
* Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
 +
* <em>and</em> 1 of the following:
 +
** Ratio of RV end-diastolic volume to BSA &ge;100 to &lt;110 mL/m<sup>2</sup> (male) or &ge;90 to &lt;100 mL/m<sup>2</sup> (female)
 +
** <em>or</em> RV ejection fraction &gt;40% to &le;45%
 +
|-
 +
| colspan="2" | '''II. Tissue characterization of wall'''
 +
|-
 +
|  '''Major'''
 +
| '''Minor'''
 +
|-
 +
| valign="top" |
 +
* Residual myocytes &lt;60% by morphometric analysis (or &lt;50% if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
 +
| valign="top" |
 +
* Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
 +
|-
 +
| colspan="2" | '''III. Repolarization abnormalities'''
 
|-
 
|-
|<li>Indien ARVD bij een familielid is vastgesteld bij obductie</li>
+
| '''Major'''
<li>Plotse hartdood (<35 jaar) bij een familielid</li>
+
| '''Minor'''
<li>Sustained of non-sustained VT's met een linker bundeltakblok</li>
+
|-
<li>Frequente extrasystolen (>1000 / 24 uur op een [[Holter]] monitor)</li>
+
| valign="top" |
<li>Verwijding en verminderde pompkracht van de rechter hartkamer</li>
+
* Inverted T waves in right precordial leads (V<sub>1</sub>, V<sub>2</sub>, and V<sub>3</sub>) or beyond in individuals &gt;14 years of age (in the absence of complete right bundle-branch block QRS &ge;120 ms)
<li>Kleine aneurysmata (ballonvormige verwijdingen) van de rechter hartkamerwand</li>
+
| valign="top" |
 +
* Inverted T waves in leads V<sub>1</sub> and V<sub>2</sub> in individuals &gt;14 years of age (in the absence of complete right bundle-branch block) or in V<sub>4</sub>, V<sub>5</sub>, or V<sub>6</sub>
 +
* Inverted T waves in leads V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, and V<sub>4</sub> in individuals &gt;14 years of age in the presence of complete right bundle-branch block
 +
|-
 +
| colspan="2" | '''IV. Depolarization/conduction abnormalities'''
 +
|-
 +
|  '''Major'''
 +
| '''Minor'''  
 +
|-
 +
| valign="top" |
 +
* Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V<sub>1</sub> to V<sub>3</sub>)
 +
|  valign="top |
 +
* Late potentials by SAECG in &ge;1 of 3 parameters in the absence of a QRS duration of &ge;110 ms on the standard ECG
 +
* Filtered QRS duration (fQRS) &ge;114 ms
 +
* Duration of terminal QRS &lt;40 <em>&micro;</em>V (low-amplitude signal duration) &ge;38 ms
 +
* Root-mean-square voltage of terminal 40 ms &le;20 <em>&micro;</em>V
 +
* Terminal activation duration of QRS &ge;55 ms measured from the nadir of the S wave to the end of the QRS, including R&acute;, in V<sub>1</sub>, V<sub>2</sub>, or V<sub>3</sub>, in the absence of complete right bundle-branch block
 +
|-
 +
| colspan="2" | '''V. Arrhythmias'''
 +
|-
 +
|  '''Major'''
 +
| '''Minor'''
 +
|-
 +
| valign="top" |
 +
* Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)
 +
|  valign="top |
 +
* Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
 +
* &gt;500 ventricular extrasystoles per 24 hours (Holter)
 +
|-
 +
| colspan="2" | '''VI. Family history'''
 +
|-
 +
|  '''Major'''
 +
| '''Minor'''
 +
|-
 +
| valign="top" |
 +
* ARVC/D confirmed in a first-degree relative who meets current Task Force criteria
 +
* ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
 +
* Identification of a pathogenic mutation<sup>&dagger;</sup> categorized as associated or probably associated with ARVC/D in the patient under evaluation
 +
|  valign="top |
 +
* History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria
 +
* Premature sudden death (&lt;35 years of age) due to suspected ARVC/D in a first-degree relative
 +
* ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative
 +
|-
 +
| colspan="2" |
 +
<ul>
 +
<li>PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage unipolar left arm lead.</li>
 +
<li>Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 minor criteria from different groups. Diagnostic terminology for revised criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different categories.</li>
 +
<li><sup>&lowast;</sup> Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.</li>
 +
<li><sup>&dagger;</sup> A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non–ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree. E.g.: in TMEM43, DSP, PKP2, DSG2, DSC2, JUP. </li>
 +
</ul>
 
|}
 
|}
{{clr}}
 
 
===Behandeling===
 
De therapie bestaat vooralsnog uit preventie van complicaties.<cite>ACC2006</cite>
 
 
*Medicatie: anti-arritmetica: Amiodarone, Sotalol; verder ace-remmers ter voorkoming van remodeling van het hart.
 
*Preventieve [[:w:nl:Internal_Cardiac_Defibrillator|ICD]] plaatsing bij patienten die ondanks optimale medicamenteuze behandeling een sustained [[Ritmestoornissen#Ventrikeltachycardie|ventriculaire tachycardie]] of [[Ritmestoornissen#Ventrikelfibrilleren|ventrikelfibrilleren]] ontwikkelen. Ook komen in aanmerking voor ICD: patiënten met een uitgebreid aangedaan hart waarbij bijvoorbeeld ook de linker kamer aangedaan is, patiënten met meerdere familie-leden die overleden zijn aan ARVD, patiënten die ondanks medicatie een syncope hebben waarbij ventrikelfibrilleren of ventrikeltachycardie niet kan worden uitgesloten.
 
*[[Ablatie]] kan toegepast worden bij patienten met recidiverende ventrikeltachycardiën ondanks medicamenteuze behandeling.
 
  
==Externe links==
+
==References==
* [http://www.cardiogenetica.nl Cardiogenetica.nl]
 
==Referenties==
 
 
<biblio>
 
<biblio>
 
#McKenna1994 pmid=8142187
 
#McKenna1994 pmid=8142187
 
#Corrado pmid=10768917
 
#Corrado pmid=10768917
 
#ACC2006 pmid=16949478
 
#ACC2006 pmid=16949478
 +
#Corr pmid=19366719
 +
#cox pmid=20215590
 +
#Crit2010 pmid=20172912
 
</biblio>
 
</biblio>

Latest revision as of 13:20, 5 May 2013

Author(s) J.S.S.G. de Jong, MD
Moderator J.S.S.G. de Jong, MD
Supervisor
some notes about authorship
ECG with an epsilon wave in V1
A section throughout the heart of an ARVC patient. (A) Transmural fatty replacement of the right ventricular free wall. (B) Myocardial atrophy is confined to the right ventricle and substantially spares the interventricular septum as well as the left ventricular free wall. [1] Reproduced with permission from BMJ Publishing Group Ltd.

Arrhythmogenic Right Ventricular Cardiomyopathy, (ARVC, or ARVD: Arrhythmogenic Right Ventricular Disease) is characterized by fatty replacement and fibrosis of the heart. Most commonly the right ventricle apex and outflow tract are involved. However the left ventricle can be affected too.[2]

As a result of the fatty replacement and fibrosis, ventricular arrhythmias are common in this disease and can lead to palpitations, syncope and sudden death. At more advanced ages right ventricular pump failure can occur.

The diagnosis is based on major and minor criteria, as published by the European Society of Cardiology.[3]

ARVC is a progressive disease. The incidence is estimated to be 1:3.000-1:10.000. Manifestations are usually seen in teenagers. Although the diagnosis is more often made in athletes, sports are not thought to have a causative relationship with the disease. ARVD can occur in families; more than 9 different mutations have been described, most often with autosomal dominant inheritance.

One unique form of ARVD, called Naxos disease (after the Greek island where it was first diagnosed), has an autosomal recessive pattern of inheritance.

Diagnosis ARVC is a difficult diagnosis to make. Therefore, the European Society of Cardiology has created a list of diagnostic criteria for the diagnosis of ARVC[3] (see table). An online calculator can help in assessing the risk in an individual patient. In 2009 these criteria were updated[4][5], see the table below.

Treatment focuses on avoiding complications.[6]

  • Medication:
    • Anti-arrhythmics: Sotalol better than Amiodarone.
    • ACE-inhibitors to prevent cardiac remodelling
  • ICD implantation is recommended for the prevention of sudden cardiac death in patients with ARVC with documented sustained VT or VF who are receiving chronic optimal medical therapy.
  • ICD implantation can be considered for the prevention of sudden cardiac death in patients with ARVC with extensive disease, including those with left ventricular involvement, 1 or more affected family member with SCD (Sudden Cardiac Death), or undiagnosed syncope when ventricular tachycardia or ventricular Fibrillation has not been excluded as the cause of syncope, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y.
  • Radiofrequency ablation can be useful as adjunctive therapy in management of patients with ARVC with recurrent ventricular tachycardia, despite optimal antiarrhythmic drug therapy.

ECG in ARVD

On ARVD.org the latest ECG criteria for ARVD are updated. To enhance detection of ECG abnormalities specific settings to record an ARVD ECG can be used: ECG settings to enhance recording of Epsilon waves.

In patients suspected to have ARVD both a normal 12 lead ECG and a Signal Averaged ECG (SAECG) are useful.

Revised Task Force Criteria ARVD / ARVC

The Revised Task Force Criteria for ARVD / ARVC
Revised Task Force Criteria
I. Global or regional dysfunction and structural alterations
Major Minor

By 2D echo:

  • Regional RV akinesia, dyskinesia, or aneurysm
  • and 1 of the following (end diastole):
    • PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA] ≥19 mm/m2)
    • PSAX RVOT ≥36 mm (corrected for body size [PSAX/BSA] ≥21 mm/m2)
    • or fractional area change ≤33%

By MRI:

  • Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
  • and 1 of the following:
    • Ratio of RV end-diastolic volume to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 (female)
    • or RV ejection fraction ≤40%

By RV angiography:

  • Regional RV akinesia, dyskinesia, or aneurysm

By 2D echo:

  • Regional RV akinesia or dyskinesia
  • and 1 of the following (end diastole):
    • PLAX RVOT ≥29 to <32 mm (corrected for body size [PLAX/BSA] ≥16 to <19 mm/m2)
    • PSAX RVOT ≥32 to <36 mm (corrected for body size [PSAX/BSA] ≥18 to <21 mm/m2)
    • or fractional area change >33% to ≤40%

By MRI:

  • Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
  • and 1 of the following:
    • Ratio of RV end-diastolic volume to BSA ≥100 to <110 mL/m2 (male) or ≥90 to <100 mL/m2 (female)
    • or RV ejection fraction >40% to ≤45%
II. Tissue characterization of wall
Major Minor
  • Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
  • Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
III. Repolarization abnormalities
Major Minor
  • Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals >14 years of age (in the absence of complete right bundle-branch block QRS ≥120 ms)
  • Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the absence of complete right bundle-branch block) or in V4, V5, or V6
  • Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of age in the presence of complete right bundle-branch block
IV. Depolarization/conduction abnormalities
Major Minor
  • Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)
  • Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS duration of ≥110 ms on the standard ECG
  • Filtered QRS duration (fQRS) ≥114 ms
  • Duration of terminal QRS <40 µV (low-amplitude signal duration) ≥38 ms
  • Root-mean-square voltage of terminal 40 ms ≤20 µV
  • Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R´, in V1, V2, or V3, in the absence of complete right bundle-branch block
V. Arrhythmias
Major Minor
  • Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)
  • Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
  • >500 ventricular extrasystoles per 24 hours (Holter)
VI. Family history
Major Minor
  • ARVC/D confirmed in a first-degree relative who meets current Task Force criteria
  • ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
  • Identification of a pathogenic mutation categorized as associated or probably associated with ARVC/D in the patient under evaluation
  • History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria
  • Premature sudden death (<35 years of age) due to suspected ARVC/D in a first-degree relative
  • ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative
  • PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage unipolar left arm lead.
  • Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 minor criteria from different groups. Diagnostic terminology for revised criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different categories.
  • Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.
  • A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non–ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree. E.g.: in TMEM43, DSP, PKP2, DSG2, DSC2, JUP.

References

Error fetching PMID 8142187:
Error fetching PMID 10768917:
Error fetching PMID 16949478:
Error fetching PMID 19366719:
Error fetching PMID 20215590:
Error fetching PMID 20172912:
  1. Error fetching PMID 10768917: [Corrado]
  2. Error fetching PMID 19366719: [Corr]
  3. Error fetching PMID 8142187: [McKenna1994]
  4. Error fetching PMID 20215590: [cox]
  5. Error fetching PMID 20172912: [Crit2010]
  6. Error fetching PMID 16949478: [ACC2006]

All Medline abstracts: PubMed | HubMed